Breaking News Nov 5, 2026 · 1 min read

ANI Pharmaceuticals offers to acquire Egetis Therapeutics to expand rare disease business

ANI Pharmaceuticals (Nasdaq: ANIP) announced a recommended public offer to acquire Sweden-based Egetis Therapeutics, per a GlobeNewswire release. The deal would expand ANI's rare disease footprint and scale its specialty pharma business.

Source:
globenewswire.com: https://www.globenewswire.com/news-release/2026/11/05/3396047/0/en/ani-pharmaceuticals-announces-offer-to-acquire-egetis-therapeutics-expanding-the-scope-and-scale-of-its-rare-disease-business.html

Not financial advice. For informational and educational purposes only.

Track your live portfolio alongside our daily institutional research

Connect your brokerage in 60 seconds and get full access to Position Tracker Substack research inside your dashboard.

Start your free trial →